300436 Fujian Cosunter Pharmaceutical
- 18.04
- +0.20+1.12%
Fujian Cosunter Pharmaceutical News
Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses
Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
Express News | Guangshengtang: The innovative hepatitis B core protein inhibitor GST-HG141 has obtained a US Patent Authorization Notice and an Australian Patent Certificate; in addition, the novel c-Met targeted drug GST-HG161 has also obtained a Peruvian Patent Author
Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development
Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now
Express News | Guangshengtang: Plans to terminate some technical service contracts
Express News | Guangshengtang: Phase II III clinical research data for a class of innovative anti-COVID-19 drugs will be published in the authoritative international journal “eClinical Medicine”
Guangshengtang (300436.SZ) subsidiaries obtained patent certificates or authorization notices for various innovative drugs
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary...
Guangshengtang (300436.SZ): Expected net loss of 260 million yuan to 298 million yuan in 2023
On January 30, Gelonghui | Guangshengtang (300436.SZ) announced that it expects net loss of 260 million yuan to 298 million yuan in 2023, deducting non-net loss of 248 million yuan to 286 million yuan, and operating income of 41 million yuan to 430 million yuan. During the reporting period, the company continued to invest in innovative drug research and development. The innovative drug GST-HG131 entered clinical phase II, GST-HG141 completed clinical phase II enrollment, and the anti-COVID-19 drug Taizhong was approved, achieving “zero breakthroughs” in the launch of innovative drugs. The company's R&D investment in 2022
Express News | Guangshengtang: Currently strengthening industrial chain cooperation and strengthening organization according to demand
Guangshengtang (300436.SZ): Thai Zhongding, an innovative anti-COVID-19 drug, has been successfully included in the scope of temporary health insurance payments
Gelonghui, January 19 | Guangshengtang (300436.SZ) said on the investor interactive platform that our innovative anti-COVID-19 drug, Thai Zhongding, has been successfully included in the scope of temporary medical insurance payments, paid in category B, and completed online registration in more than a dozen provinces and cities, including Beijing, Fujian, Hebei, and Shanghai. Currently, in order to deal with the risks posed by the COVID-19 variant JN.1, some provinces and municipalities have included Thai Zhongding in key drug reserve procurement. This is part of the normal sales and operation activities of enterprises, and there are no matters that should be disclosed but not disclosed.
Guangshengtang (300436.SZ) plans to establish Guangfu with Aotai Phase 9 to promote international business development
Guangshengtang (300436.SZ) announced that the company plans to invest in the 9th phase of the Fuzhou Aotai Investment Partnership (limited partnership) with the related party...
Guangshengtang (300436.SZ): Proposes to establish Guang Fulai, a holding subsidiary for export business
Gelonghui, January 9丨Guangshengtang (300436.SZ) announced that in order to implement the company's internationalization strategy, expand the international business field of the company's drugs, especially anti-coronavirus drugs, promote the development and growth of the international business scale and further enhance the company's comprehensive strength, Fujian Guangshengtang Pharmaceutical Co., Ltd. plans to jointly invest in the establishment of the relevant party Fuzhou Aotai Phase 9 Investment Partnership (Limited Partnership) (“Aotai Phase 9”) (“Aotai Phase 9” for short). Guangfulai's registered capital is RMB 50 million
Guangshengtang: The first case of the Phase IIa clinical trial of an innovative drug for hepatitis B treatment was successfully enrolled
Gelonghui, January 3 | Guangshengtang announced that the first phase IIa clinical trial of GST-HG131, an innovative hepatitis B treatment drug of Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a holding subsidiary, was successfully enrolled for administration on January 3, 2024.
Guangshengtang (300436.SZ): Plans to terminate the “Jiangsu ZTE Pharmaceutical Workshop Construction Project” and raise the remaining capital permanently to supplement working capital
Gelonghui, December 29丨Guangshengtang (300436.SZ) announced that the company held the 27th meeting of the 4th board of directors and the 24th meeting of the fourth board of supervisors on December 29, 2023 to review and pass the “Proposal on Terminating Some Fund-raising Investment Projects and Permanently Supplementing Liquidity”. In order to improve the efficiency of the use of raised funds and reduce the risk of capital raised investment, according to the actual progress of the company's fund-raising projects and changes in the market environment, the company agreed to “Jiangsu ZTE Formulation” in the fund-raising investment project to issue shares to specific targets “Workshop construction project” terminated
Guangshengtang (300436.SZ): GST-HG141, an innovative drug for the treatment of hepatitis B, completed the Phase II clinical trial plan and the number of cases enrolled
Gelonghui, December 29丨Guangshengtang (300436.SZ) announced that the innovative hepatitis B treatment drug GST-HG141 of Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary, has completed the enrollment of all infected patients planned in accordance with the requirements of the Phase II clinical plan. The hepatitis B core protein inhibitor GST-HG141 (Chinese generic name: Nerecovir, World Health Organization (WHO) International Non-Patent Name (INN): Neracorvir) is a new class of anti-hepatitis B virus drugs with a new target, which can inhibit the shelling and assembly of the HBV (hepatitis B virus) capsid.
Guangshengtang (300436.SZ): A class of innovative drugs, Thailand, will be included in temporary health insurance payments
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary...
Guangshengtang (300436.SZ): At present, the company's anti-coronavirus oral small-molecule 3CL protease inhibitor, a class of innovative drug Taizhongding, has been approved for marketing
On December 21, Guangshengtang (300436.SZ) said on the investor interactive platform on December 21 that at present, the company's anti-coronavirus oral small-molecule 3CL protease inhibitor, the innovative drug Taizhongding (atetetevir GST-HG171 combined with ritonavir tablets) has been approved for marketing. Among them, attetevir GST-HG171 is a highly active and highly selective oral 3CL protease inhibitor that can exert a broad spectrum of inhibitory effects on the coronavirus and its derived mutated strains. Clinical research results confirm that Thailand and China can definitely significantly shorten the clinical rehabilitation of patients infected with COVID-19
Guangshengtang (300436.SZ): Solofovir tablets (progandine), the core drug for curing hepatitis C, obtained drug production registration approval
Gelonghui November 27丨Guangshengtang (300436.SZ) announced that recently, Fujian Guangshengtang Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” approved and issued by the State Drug Administration regarding the company's central drug for curing hepatitis C, solifosbuvir tablets (valgandine). The approval of solifosbuvir tablets for marketing and production will further improve the company's product layout in the field of liver health, strengthen its market share and leading position in the field of liver medicine, build the company's “liver disease expert” series brand, provide the company with new growth points, and help the company innovate, transform and develop.
Guangshengtang: The holding subsidiary, the anti-COVID-19 drug in Thailand and China, has been approved for listing
Gelonghui, November 24 | Guangshengtang announced in the evening that Guangsheng Zhonglin, a subsidiary of the company's innovative drug holding company, anti-coronavirus oral small molecule 3CL protease inhibitors, attetetevir tablets (project code: GST-HG171) /ritonavir tablets combination packaging (product name:) /ritonavir tablets (trade name: taizhongding) was conditionally approved for listing by the State Drug Administration and received a “Drug Registration Certificate”.
Guangshengtang (300436.SZ) subsidiary's first-class innovative drug, Thai Zhongding (atetetevir tablets combined with ritonavir tablets), was approved for listing
Guangshengtang (300436.SZ) issued an announcement. On November 23, Fujian Guangshengzhong, the company's innovative drug holding subsidiary...
Guangshengtang (300436.SZ), a class of innovative drug, Taizhongding (atetetevir tablets in combination with ritonavir tablets), a new drug, was accepted
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary...
Analysis
Price Target
No Data
